Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REN001 in Primary Mitochondrial Myopathy
2020-002855-40Phase 2Completed
- Sponsor
- Reneo Pharmaceuticals
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary mitochondrial myopathies (PMM) and Mitochondrial myopathies (MM) comparing REN001 with Placebo (2 arms). Primary endpoint: Change from baseline in distance walked during the 12 minute walk test. Started Feb 2021; status: completed.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathies (PMM)Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2020-002855-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002855-40.